Leadership team appointments at Metagenomi

15 March 2022

Metagenomi, a California, USA-based genetic medicines company with a versatile portfolio of next-generation gene editing tools, today announced the appointment of Christine Foster, as chief business officer and Alan Cohen, as chief medical officer and senior vice president of Monogenic Diseases.

Dr Foster joins Metagenomi from Intellia Therapeutics (Nasdaq: NTLA), where she served as SVP of business development. As CBO at Metagenomi, she will oversee all facets of new business ventures, partnerships and collaborations, and licensing deals.

Dr Cohen joins Metagenomi from Eidos Therapeutics, a BridgeBio (Nasdaq: BBIO) company, where he focused primarily on the transthyretin amyloidosis heart failure program, while serving as VP of global medical affairs. As CMO at Metagenomi, he will support the company’s emerging novel in vivo clinical development programs in monogenic diseases, such as hemophilia A (HemA) and cystic fibrosis (CF).

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK